Stem Cell Therapy

Evidence for orthopedic applications (knee osteoarthritis) has strengthened: a 2025 meta-analysis of 8 RCTs (502 patients, Stem Cell Research & Therapy) found significant WOMAC and pain improvements at 6 and 12 months, with adipose-derived and higher-dose (1.0-2.0x10^8 cell) preparations performing best and no significant increase in serious adverse events. A larger 2026 meta-analysis of 28 RCTs (Clinical Rheumatology) confirmed modest but significant pain and function benefits, though MRI-based structural (cartilage) outcomes were unchanged -- the therapy appears symptom-modifying, not disease-modifying -- and local reactions (injection-site pain, joint swelling) were more common in treated patients than placebo. For anti-aging/frailty applications specifically, a randomized Phase 2b trial of laromestrocel (an investigational allogeneic bone-marrow-derived MSC product from Longeveron, N=148, published in Cell Stem Cell, Feb 2026) showed dose-dependent improvement in 6-minute walk distance (~63m vs placebo at month 9) and reduced frailty classification, with a favorable safety profile. This is the first placebo-controlled RCT evidence specifically for aging-related frailty, though it involves one investigational, not-yet-FDA-approved product and should not be conflated with the heterogeneous, often-unregulated stem cell treatments sold at general wellness/anti-aging clinics. Regulatory scrutiny of clinic-based stem cell and exosome offerings continues: the FDA issued new warning letters in 2026 (e.g., against unapproved umbilical cord and exosome products, citing reports of serious adverse events), and a March 2026 PNAS commentary noted that most clinics operate outside meaningful FDA oversight, with documented patient harm and misleading marketing claims common industry-wide. Muse (Multilineage-differentiating Stress-Enduring) cells are a newer, distinct stem cell subtype under active clinical investigation, separate from the MSC/adipose/bone-marrow products discussed above. In a randomized, double-blind, placebo-controlled trial of CL2020 (an allogeneic Muse cell product) in subacute ischemic stroke (n=35, published J Cereb Blood Flow Metab, 2023), 40% of treated patients reached a good functional outcome (modified Rankin Scale <=2) at 12 weeks vs. 10% on placebo, with greater upper-limb motor recovery; adverse events were common (96%) but consistent with the underlying stroke population, and no treatment-related discontinuations occurred, though one serious neurological adverse event (status epilepticus) was reported in the treatment arm. Muse cell products are also in earlier-stage trials for traumatic spinal cord injury, ALS, epidermolysis bullosa, neonatal hypoxic-ischemic encephalopathy, and traumatic brain injury (e.g., NCT07326059). These findings are specific to the CL2020 investigational product and specific conditions studied (largely neurological/ischemic injury, not general anti-aging use); Muse cell therapy remains investigational, is not FDA-approved, and is not currently available as a marketed anti-aging or wellness-clinic treatment.

Evidence Scale